Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALSA: Extended Adjuvant Anastrozole in HR+ Breast Cancer
NCT00295620Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2004
- Primary completion
- Jun 2017
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anastrozole in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Disease-free Survival After Prolonged Endocrine Treatment at 8.5 years. Started Mar 2004; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00295620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295620.